Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2005 2
2006 2
2007 8
2008 2
2009 1
2010 5
2011 3
2012 5
2013 2
2014 3
2015 5
2016 8
2017 7
2018 12
2019 9
2020 17
2021 20
2022 25
2023 16
2024 12
2025 18
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators. Borghaei H, et al. Ann Oncol. 2024 Jan;35(1):66-76. doi: 10.1016/j.annonc.2023.10.004. Epub 2023 Oct 20. Ann Oncol. 2024. PMID: 37866811 Free article. Clinical Trial.
Reply by Authors.
Ramasamy R, Masterson TA, Best JC, Bitran J, Ibrahim E, Molina M, Kaiser UB, Miao F, Reis IM. Ramasamy R, et al. Among authors: ibrahim e. J Urol. 2020 Sep;204(3):563. doi: 10.1097/JU.0000000000001078.03. Epub 2020 Jun 23. J Urol. 2020. PMID: 32574104 No abstract available.
A phase 2 randomized, placebo-controlled crossover trial to evaluate safety and efficacy of platelet-rich plasma injections for Peyronie's disease: clinical trial update.
Ledesma BR, Velasquez DA, Egemba C, Molina M, Ibrahim E, Costantini-Mesquita F, Deebel NA, Han S, Reis IM, Saltzman R, Ramasamy R. Ledesma BR, et al. Among authors: ibrahim e. Int J Impot Res. 2024 Dec;36(8):813-817. doi: 10.1038/s41443-024-00844-3. Epub 2024 Feb 29. Int J Impot Res. 2024. PMID: 38424354 Clinical Trial.
Mixtures Recomposition by Neural Nets: A Multidisciplinary Overview.
Nicolle A, Deng S, Ihme M, Kuzhagaliyeva N, Ibrahim EA, Farooq A. Nicolle A, et al. Among authors: ibrahim ea. J Chem Inf Model. 2024 Feb 12;64(3):597-620. doi: 10.1021/acs.jcim.3c01633. Epub 2024 Jan 29. J Chem Inf Model. 2024. PMID: 38284618 Review.
168 results